SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study
SGLT2i are now primarily used to treat HF. Their therapeutic potential in CKD appears to be still underestimated. Overall, compliance with guidelines appears satisfactory.
Authors
- P. Noize
- Julien Bezin (ORCID: https://orcid.org/0000-0002-2568-1928)
- Romain Griffier
- Sibylle de Germay
- Antoine Pariente
- Maxime Demourgues
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Bordeaux Population Health (FR)
- Département d'Informatique (FR)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1111/fcp.70076
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00